2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
26
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
8
Adenocarcinoma
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
HER2-positive Breast Cancer
3
Advanced Solid Tumor
3
Advanced Breast Cancer
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm, Residual
2
Meningeal Carcinomatosis
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Breast Cancer With Brain Metastasis
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Interventions
pembrolizumab
189
Cisplatin
47
Paclitaxel
45
Carboplatin
44
lenvatinib
31
Docetaxel
23
Pemetrexed
21
Fluorouracil
20
Capecitabine
17
Gemcitabine
15
Oxaliplatin
14
Saline Solution
13
Albumin-Bound Paclitaxel
11
130-nm albumin-bound paclitaxel
10
epacadostat
9
Leucovorin
9
Cetuximab
9
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
enzalutamide
5
durvalumab
5
belzutifan
5
Nivolumab
5
Dexamethasone
5
Surgical Procedures, Operative
4
Radiotherapy
4
trifluridine tipiracil drug combination
3
spartalizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
trastuzumab deruxtecan
×
Clear all
NCT06989112
2026-05-06
DE-01
AstraZeneca
Phase 3
Recruiting
600 enrolled